OTC DOXYLAMINE-CONTAINING ANTIHISTAMINES TO BE INCLUDED IN FINAL MONOGRAPH
This article was originally published in The Tan Sheet
Executive Summary
OTC DOXYLAMINE-CONTAINING ANTIHISTAMINES TO BE INCLUDED IN FINAL MONOGRAPH and will not require tumorigenicity label warnings, according to an amendment to the antihistamine monograph published by FDA in the Jan. 28 Federal Register. The amendment notice follows the recommendations of the Nonprescription Drugs Advisory Committee at a June 28 meeting ("The Tan Sheet" July 5, 1993, p. 5).
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning